A Randomized Double-blind, Placebo-controlled, Non-confirmatory Study to Assess Safety, Tolerability, PK, and PD of Single Ascending and Multiple Doses of ISIS 681257 in Healthy Japanese Participants
Latest Information Update: 25 Apr 2022
At a glance
- Drugs Pelacarsen (Primary)
- Indications Hyperlipoproteinaemia
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
Most Recent Events
- 25 Apr 2022 New trial record